Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma

Inclusion Criteria:

* 18 years of age or over.
* At least one suspected soft tissue sarcoma tumor that is considered by the investigator to be: (1) accessible for percutaneous injection and (2) at least 2.5 cm in shortest dimension for patients undergoing an incisional biopsy, or at least 3 cm in shortest dimension for patients undergoing an excisional biopsy/tumor resection. Tumors should not be selected if the Investigator believes them to be necrotic or exhibit signs of radiation-induced fibrosis.
* Prior surgical evaluation and plan for surgical biopsy or surgery to remove the tumor being injected.
* ECOG performance status of 0-2 (or a Karnofsky performance status of \>50%)
* Labs required for enrollment (prior to microinjection):

  * Absolute neutrophil count \> 1000/mm3
  * Platelet count \> 50,000/mm3
  * Hematocrit \> 25%
  * Creatinine \<3.0 mg/dl
  * Total Bilirubin \<4.0 mg/dl
  * Bilirubin \<4.0 mg/dl, SGOT ≤ 1.5 times the upper limit of normal
  * PT and PTT ≤ 1.5 times the upper limit of normal

Exclusion Criteria:

* Subjects with active fungal, viral, or bacterial infections.
* Pregnant women.
* Inability to give informed consent.
* Current treatment with anticoagulation such as warfarin or low-molecular-weight heparin.
* Tumors near critical structures such as those located near or in the brain or spine. This assessment will be determined by the treating clinician.